Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Pancreatic Neoplasms 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1

Interventions

Radiotherapy 9Vincristine 8Dactinomycin 8Cyclophosphamide 8Ifosfamide 6Radiation 5Filgrastim 5Doxorubicin 5Irinotecan 4sargramostim 3pegfilgrastim 2brostallicin 2Vinorelbine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trioctyl phosphine oxide 1perifosine 1lorvotuzumab mertansine 1irinotecan sucrosofate 1imetelstat 1exatecan 1etoposide phosphate 1X-Rays 1Trabectedin 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Rhabdomyosarcoma × irinotecan sucrosofate × Clear all
NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡